evolcSign inStart free
Menu

Draig Therapeutics

Develops neuropsychiatric drug therapies for patients with depression and other brain disorders

Cardiff, United KingdomFounded 2021draigtherapeutics.comWebsite technologies

+ Add to sales board

Highlights

  • New on EvolcAdded 2026-10-31

About Draig Therapeutics

Draig Therapeutics develops AMPA and GABAA receptor modulators for neuropsychiatric disorders. Its lead program, DT-101, is a Phase 2 AMPA receptor potentiator for major depressive disorder.

The company was co-founded in 2024 by Cardiff University and SV Health Investors. Its founders draw on scientific expertise at Cardiff University’s Medicines Discovery Institute and experience in drug development.

Product: Drug development programs focused on AMPA and GABAA receptor modulators for neuropsychiatric disorders.

Jobs at Draig Therapeutics

No open positions listed right now.

Leadership

  • John Atack · Head of Biology & Founder
    Source: company website
  • Ruth McKernan · Founder Draig Therapeutics; Operating Partner at SV Health Investors
    Source: company website
  • Simon Ward · Chief Scientific Officer & Founder
    Source: company website
  • Ivana Magovčević-Liebisch · President & Chief Executive Officer
    Source: company website
  • Stephanie Fedak · SVP, People & Culture and Head of HR
    Source: company website

More biotech & pharma companies

  • Duke Street Bio

    Develops cancer therapies targeting DNA damage repair deficiencies for patients with cancer
    London, United KingdomBiotech & pharmaFounded 2020
    New on Evolc

  • Elasmogen

    Biopharma developing ELN28, a dual-acting TNFα and JAK inhibitor conjugate for hidradenitis suppurativa patients
    Foresterhill, United KingdomBiotech & pharmaFounded 2014
    New on Evolc

  • Eleventx

    Extended-release RNA medicines for chronic disease, starting in cardiometabolic, developed with pharma partners
    Cambridge, United KingdomBiotech & pharma2 open jobs

  • Enara Bio

    Cancer immunotherapies for patients with solid tumors, developed using dark-antigen discovery and T-cell engager platforms
    Oxford, United KingdomBiotech & pharmaFounded 2016
    New on Evolc

  • Ensocell

    AI-driven discovery of precision therapies for fibrotic and autoimmune diseases using human biological data
    United KingdomBiotech & pharma1 open job
    New on Evolc

  • Enterobiotix

    Clinical-stage microbiome therapeutics developing the oral drug EBX-102-02 for irritable bowel syndrome and related gut and liver diseases
    Bellshill, United KingdomBiotech & pharmaFounded 2017
    New on Evolc

All biotech & pharma companies →

Website technologies

Older, unverified list. Detection dates and supporting evidence are not yet available.

  • Cloudflare
  • WordPress